Last reviewed · How we verify

NCT05925426

Defining The Quality Of Intraoperatively Salvaged Blood For Deformity Surgery

Completed Last updated 11 March 2025
What this trial tests

trial in Spinal Deformity in 103 participants. Completed in 30 September 2023.

Timeline
1 July 2022
Primary endpoint
30 June 2023
30 September 2023

Quick facts

Lead sponsorNYU Langone Health
StatusCompleted
Study typeOBSERVATIONAL
Enrollment103
Start date1 July 2022
Primary completion30 June 2023
Estimated completion30 September 2023
Sites1 location across United States

Conditions studied

Sponsor

NYU Langone Health — full company profile →

Who can join

Eligibility, any sex, with Spinal Deformity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The actual quality of Red Blood Cells (RBCs) salvaged during spinal deformity surgery has never been rigorously evaluated. To characterize the usefulness of intraoperatively salvaged RBCs in spinal deformity surgery. The study team hopes to answer the following questions: 1) What is the quality of RBCs salvaged during spine surgery? 2) Does intraoperatively transfused RBC salvage impact clinical outcomes?

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Spinal Deformity

Currently open trials in the same condition.

Other NYU Langone Health trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05925426.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing